BUY Lupin Limited — Rajesh Palviya, Axis Securities
byRajesh Palviya, Axis SecuritiesHorizon: NA (inferred Swing (≤2wk))17 Aug 2026via CNBC Awaaz.
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
Lupin shares in focus after USFDA nod for drug to treat excessive daytime sleepiness
NewsEt-Markets·18 Aug · today
Lupin Ltd has received approval from the U.S. FDA for its Pitolisant Tablets. This approval is a significant step for the company's pharmaceutical offerings.
BSE · Company Update·17 Aug · today
Lupin Limited announced that the U.S. FDA has approved its Pitolisant Tablets. This approval is a significant step for the company's product portfolio.
NSE · Press Release·17 Aug · today
Lupin wins US FDA nod for sodium zirconium cyclosilicate to treat hyperkalemia
NewsCnbc-Tv18·10 Aug · 1w ago
Lupin announced that its Sodium Zirconium Cyclosilicate for Oral Suspension has been approved in the United States.
BSE · Company Update·10 Aug · 1w ago
Nothing found in this tip’s window yet.
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.